Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Second-generation antipsychotic augmentation

20 evidence topics · 12 sources

Aripiprazole label: change in MADRS total score at week 6
StudyPlacebo-subtracted difference in MADRS change (95% CI)
Study 1“-2.84 (-4.53, -1.15)”
Study 2“-3.01 (-4.66, -1.37)”
Brexpiprazole label: change in MADRS total score at week 6
Study and dosePlacebo-subtracted difference in MADRS change (95% CI)
Study 1, 2 mg/day“-3.2 (-4.9, -1.5)”
Study 2, 1 mg/day“-1.3 (-2.7, 0.1)”
Study 2, 3 mg/day“-2.0 (-3.4, -0.5)”